Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes
Description
The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs. MeSH
Hierarchy View
Subtype Terms (65)
Arrhythmias, Cardiac
122 drugs (90 approved, 32 experimental)
Ascites
80 drugs (46 approved, 34 experimental)
Atrial Remodeling
3 approved drugs
Cardiotoxicity
68 drugs (58 approved, 10 experimental)
Chromosome Aberrations
35 drugs (31 approved, 4 experimental)
Death
26 drugs (17 approved, 9 experimental)
Dehydration
20 drugs (14 approved, 6 experimental)
Delayed Graft Function
25 drugs (17 approved, 8 experimental)
Disease
10 drugs (7 approved, 3 experimental)
Disease Attributes
3 drugs (1 approved, 2 experimental)
Dysbiosis
52 drugs (12 approved, 40 experimental)
Emphysema
43 drugs (33 approved, 10 experimental)
Extravasation of Diagnostic and Therapeutic Materials
4 approved drugs
Femoracetabular Impingement
12 drugs (8 approved, 4 experimental)
Fibrosis
227 drugs (157 approved, 70 experimental)
Frailty
42 drugs (22 approved, 20 experimental)
Granuloma
39 drugs (30 approved, 9 experimental)
Granulomatosis, Orofacial
1 approved drug
Growth Disorders
35 drugs (17 approved, 18 experimental)
Hemolysis
21 drugs (13 approved, 8 experimental)
Hemorrhage
194 drugs (134 approved, 60 experimental)
Hyperammonemia
7 drugs (5 approved, 2 experimental)
Hyperbilirubinemia
10 drugs (5 approved, 5 experimental)
Hyperplasia
30 drugs (20 approved, 10 experimental)
Hyperuricemia
65 drugs (25 approved, 40 experimental)
Hypovolemia
18 drugs (11 approved, 7 experimental)
Inflammation
621 drugs (277 approved, 344 experimental)
Intraoperative Complications
15 drugs (13 approved, 2 experimental)
Ischemia
65 drugs (39 approved, 26 experimental)
Leukocytosis
1 experimental drug
Long Term Adverse Effects
2 drugs (1 approved, 1 experimental)
Menstruation Disturbances
39 drugs (28 approved, 11 experimental)
Metaplasia
2 approved drugs
Muscle Weakness
53 drugs (34 approved, 19 experimental)
Necrosis
6 drugs (4 approved, 2 experimental)
Neointima
2 approved drugs
Neoplastic Processes
2 drugs (1 approved, 1 experimental)
Nerve Degeneration
19 drugs (13 approved, 6 experimental)
Ossification, Heterotopic
7 drugs (5 approved, 2 experimental)
Ototoxicity
15 drugs (10 approved, 5 experimental)
Pigmentation Disorders
8 drugs (7 approved, 1 experimental)
Postoperative Complications
232 drugs (173 approved, 59 experimental)
Protein Aggregation, Pathological
Respiratory Aspiration
28 drugs (25 approved, 3 experimental)
Sclerosis
74 drugs (51 approved, 23 experimental)
Shock
53 drugs (38 approved, 15 experimental)
Toxic Optic Neuropathy
3 drugs (2 approved, 1 experimental)
Ulcer
85 drugs (47 approved, 38 experimental)
Vascular Remodeling
2 approved drugs
Yang Deficiency
2 approved drugs
Yin Deficiency
2 approved drugs
Phase 4 Indicated Drugs (5)
Phase 1 Indicated Drugs (5)
Other Experimental Indicated Drugs (8)
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (23)
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
